Case Study: Launch Pricing Strategy for a Novel Oral Oncolytic
What Our Client Needed
In preparation for their new product launch, a payer strategy lead needed to develop robust pricing and market access strategy for an oral therapy targeting a biomarker-positive subset in a blood cancer.
Aquilae CG has deep subject matter expertise within the pricing and market access space and has experience bridging insights of these projects into broader commercial strategy development in preparation for the launch of innovative products, which allowed us to be a credible thought partner.
Aquilae CG leveraged secondary research, primary research, and data analyses to develop robust and defensible pricing and access assumptions within an aggressive project timeline.
We used a combination of pricing analogues, primary research with payer decision makers, KOLs and patient advocacy groups to evaluate price/access tradeoffs at the payer and hospital/institution levels.
In addition, we determined the impact of price on formulary placement and thus patient out-of-pocket costs which in turn may impact demand and fulfillment.
Our work included robust forecasting models to inform strategic forecasting efforts and identified an optimal price range that balanced both value optimization (price references, payers & public perceptions) and business considerations (price-volume tradeoffs, competitive dynamics and life cycle management).
Client successfully launched the new oral therapy at our recommended target price.